DMAC

NASDAQ open

DiaMedica Therapeutics

8.25 USD
▲+0.23+2.87%
盘后 8.98 0.00%
2026-11-20
市值
$445.15M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
5.25 – 11.00
成交量
226.66K
Beta
0.94
目标价
16.25
52W 低 5.2552W 高 11.00
价格走势

公司简介

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...